Their findings suggest that TRPA1 inhibition may represent a promising therapeutic strategy for mitigating myocardial fibrosis in diabetic patients, potentially reducing the risk of congestive heart failure, and improving overall cardiac function. Here, TRPA1 is linked to congestive heart failure.